What is claimed is:
`
`l.
`
`A film dosage form for trans-mucosal medication-assisted treatment for opioid addiction,
`
`the film dosage form comprising:
`
`a) an amount of buprenorphine, or an equivalent amount of a pharmaceutically
`
`acceptable salt thereof, sufficient to provide an average buprenorphine Cmax of less than
`
`about 7 ng/ml and an average buprenorphine AUC0.48 of less than 40 (hrs*ng)/ml,
`
`b) naloxone or a pharmaceutically acceptable salt thereof; and
`
`c) at
`
`least one non-gelatin polymeric film-forming material
`
`in which the
`
`buprenorphine or the equivalent amount of the pharmaceutically acceptable salt thereof
`
`and the naloxone or the pharmaceutically acceptable salt
`
`thereof, are dissolved or
`
`homogeneously dispersed,
`
`the buprenorphine or the equivalent amount of the pharmaceutically acceptable
`
`salt thereof and the naloxone or the pharmaceutically acceptable salt thereof being
`
`present in the film dosage form in a weight ratio of from 1:1 to 10:1,
`
`wherein, the film dosage form releases substantially all of the buprenorphine or
`
`the pharmaceutically acceptable salt thereof and approximately substantially all of the
`
`naloxone or the pharmaceutically acceptable salt thereof into contact with a mucosal
`
`surface of the oral cavity within less than 5 minutes after contacting the mucosal surface.
`
`2.
`
`The film dosage form of claim 1, wherein the film dosage form further comprises a pH
`
`modifier.
`
`-24-
`
`

`

`The film dosage form of claim 2, wherein the pH modifier is selected from the group
`
`consisting of citric acid, tartaric acid, phosphoric acid, hydrochloric acid, and maleic
`
`acid.
`
`The film dosage form of claim 1, wherein the film dosage form is mucoadhesive.
`
`The film dosage form of claim 1, wherein the non-gelatin polymeric film-forming
`
`material is a modified cellulose material.
`
`The film dosage form of claim 5, wherein the modified cellulose material is a cellulose
`
`ether.
`
`The film dosage form of claim 6, wherein the cellulose ether is selected from the group
`
`consisting of hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC),
`
`hydroxyethylmethylcellulose (HEMC), hydroxyethylcellulose (HEC), methylcellulose
`
`(MC), and carboxymethylcellulose (CMC).
`
`The film dosage form of claim 1, wherein the amount of buprenorphine is from 2 mg to
`
`16 mg.
`
`The film dosage form of claim 8, wherein the amount of buprenorphine is 2 mg, 4 mg, 8
`
`mg, or 16 mg.
`
`The film dosage form of claim 1, wherein the weight ratio is 2:1 to 8:1.
`
`The film dosage form of claim 1, wherein the film dosage form further comprises at least
`
`one of sodium dihydrogen or disodiumhydrogen phosphate, sodium tartrate, sodium
`
`ascorbate, citric acid, tartartic acid, adipinic acid, ascorbic acid, acetic acid, or lactic acid.
`
`10.
`
`11.
`
`-25-
`
`

`

`12.
`
`The film dosage form of claim 1, wherein the film dosage form exhibits a tmax from
`
`approximately 45 to approximately 90 minutes.
`
`13.
`
`The film dosage form of claim 1, further comprising a flavoring agent.
`
`14.
`
`The film dosage form of claim 13, wherein the flavoring agent is selected from the group
`
`consisting of mint, raspberry, licorice, orange, lemon, grapefruit, caramel, vanilla, cherry,
`
`grape, and combinations thereof.
`
`821959172
`
`-26-
`
`

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

PTO Denying Access

Refresh this Document
Go to the Docket